Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company also provided 48-week data from the Phase II-B portion of AZURE-1, discussed plans for […]